S&P 500   3,819.59 (+0.00%)
DOW   31,298.32 (+0.09%)
QQQ   311.01 (+0.60%)
AAPL   123.04 (+0.80%)
MSFT   231.49 (+1.73%)
FB   262.43 (+2.75%)
GOOGL   2,042.49 (+1.55%)
TSLA   653.32 (+0.02%)
AMZN   3,049.37 (+1.48%)
NVDA   509.08 (-0.61%)
BABA   234.61 (-0.70%)
CGC   31.93 (-3.94%)
GE   13.71 (+2.01%)
MU   87.16 (-2.19%)
NIO   40.97 (-1.35%)
AMD   80.48 (-0.47%)
T   28.99 (+0.94%)
F   12.20 (+0.25%)
ACB   10.09 (-3.54%)
DIS   189.85 (-1.25%)
BA   231.22 (+1.16%)
NFLX   527.12 (+1.23%)
PFE   34.79 (+1.16%)
S&P 500   3,819.59 (+0.00%)
DOW   31,298.32 (+0.09%)
QQQ   311.01 (+0.60%)
AAPL   123.04 (+0.80%)
MSFT   231.49 (+1.73%)
FB   262.43 (+2.75%)
GOOGL   2,042.49 (+1.55%)
TSLA   653.32 (+0.02%)
AMZN   3,049.37 (+1.48%)
NVDA   509.08 (-0.61%)
BABA   234.61 (-0.70%)
CGC   31.93 (-3.94%)
GE   13.71 (+2.01%)
MU   87.16 (-2.19%)
NIO   40.97 (-1.35%)
AMD   80.48 (-0.47%)
T   28.99 (+0.94%)
F   12.20 (+0.25%)
ACB   10.09 (-3.54%)
DIS   189.85 (-1.25%)
BA   231.22 (+1.16%)
NFLX   527.12 (+1.23%)
PFE   34.79 (+1.16%)
S&P 500   3,819.59 (+0.00%)
DOW   31,298.32 (+0.09%)
QQQ   311.01 (+0.60%)
AAPL   123.04 (+0.80%)
MSFT   231.49 (+1.73%)
FB   262.43 (+2.75%)
GOOGL   2,042.49 (+1.55%)
TSLA   653.32 (+0.02%)
AMZN   3,049.37 (+1.48%)
NVDA   509.08 (-0.61%)
BABA   234.61 (-0.70%)
CGC   31.93 (-3.94%)
GE   13.71 (+2.01%)
MU   87.16 (-2.19%)
NIO   40.97 (-1.35%)
AMD   80.48 (-0.47%)
T   28.99 (+0.94%)
F   12.20 (+0.25%)
ACB   10.09 (-3.54%)
DIS   189.85 (-1.25%)
BA   231.22 (+1.16%)
NFLX   527.12 (+1.23%)
PFE   34.79 (+1.16%)
S&P 500   3,819.59 (+0.00%)
DOW   31,298.32 (+0.09%)
QQQ   311.01 (+0.60%)
AAPL   123.04 (+0.80%)
MSFT   231.49 (+1.73%)
FB   262.43 (+2.75%)
GOOGL   2,042.49 (+1.55%)
TSLA   653.32 (+0.02%)
AMZN   3,049.37 (+1.48%)
NVDA   509.08 (-0.61%)
BABA   234.61 (-0.70%)
CGC   31.93 (-3.94%)
GE   13.71 (+2.01%)
MU   87.16 (-2.19%)
NIO   40.97 (-1.35%)
AMD   80.48 (-0.47%)
T   28.99 (+0.94%)
F   12.20 (+0.25%)
ACB   10.09 (-3.54%)
DIS   189.85 (-1.25%)
BA   231.22 (+1.16%)
NFLX   527.12 (+1.23%)
PFE   34.79 (+1.16%)
Log in
CVE:LBL

Lattice Biologics Competitors

C$0.04
-0.01 (-10.00 %)
(As of 03/4/2021 10:59 AM ET)
Add
Compare
Today's Range
C$0.05
Now: C$0.05
C$0.05
50-Day Range
C$0.00
MA: C$0.07
C$0.13
52-Week Range
C$0.02
Now: C$0.05
C$0.21
Volume245,000 shs
Average Volume842,412 shs
Market CapitalizationC$5.77 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Lattice Biologics (CVE:LBL) Vs. SUGR, NU, AQS, THCX, GLH, and ACG

Should you be buying LBL stock or one of its competitors? Companies in the industry of "drug manufacturers - specialty & generic" are considered alternatives and competitors to Lattice Biologics, including SugarBud Craft Growers Corp. (SUGR.V) (SUGR), NeutriSci International (NU), Aequus Pharmaceuticals (AQS), (THCX.V) (THCX), 31444 (GLH), and 438280 (ACG).

Lattice Biologics (CVE:LBL) and SugarBud Craft Growers Corp. (SUGR.V) (CVE:SUGR) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and earnings.

Profitability

This table compares Lattice Biologics and SugarBud Craft Growers Corp. (SUGR.V)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Lattice BiologicsN/AN/AN/A
SugarBud Craft Growers Corp. (SUGR.V)N/AN/AN/A

Analyst Ratings

This is a summary of current ratings for Lattice Biologics and SugarBud Craft Growers Corp. (SUGR.V), as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Lattice Biologics0000N/A
SugarBud Craft Growers Corp. (SUGR.V)0000N/A

Earnings and Valuation

This table compares Lattice Biologics and SugarBud Craft Growers Corp. (SUGR.V)'s gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lattice BiologicsC$2.46 million2.34C$-1,795,052.00C($0.01)-3.21
SugarBud Craft Growers Corp. (SUGR.V)C$66,906.00552.49C$-473,614,575.00C($1.03)-0.08

Lattice Biologics has higher revenue and earnings than SugarBud Craft Growers Corp. (SUGR.V). Lattice Biologics is trading at a lower price-to-earnings ratio than SugarBud Craft Growers Corp. (SUGR.V), indicating that it is currently the more affordable of the two stocks.

Summary

Lattice Biologics beats SugarBud Craft Growers Corp. (SUGR.V) on 3 of the 5 factors compared between the two stocks.

Lattice Biologics (CVE:LBL) and NeutriSci International (CVE:NU) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and earnings.

Profitability

This table compares Lattice Biologics and NeutriSci International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Lattice BiologicsN/AN/AN/A
NeutriSci InternationalN/AN/AN/A

Analyst Ratings

This is a summary of current ratings for Lattice Biologics and NeutriSci International, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Lattice Biologics0000N/A
NeutriSci International0000N/A

Earnings and Valuation

This table compares Lattice Biologics and NeutriSci International's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lattice BiologicsC$2.46 million2.34C$-1,795,052.00C($0.01)-3.21
NeutriSci InternationalC$69,626.00317.51C$-1,982,032.00C($0.01)-11.15

Lattice Biologics has higher revenue and earnings than NeutriSci International. NeutriSci International is trading at a lower price-to-earnings ratio than Lattice Biologics, indicating that it is currently the more affordable of the two stocks.

Summary

Lattice Biologics beats NeutriSci International on 3 of the 5 factors compared between the two stocks.

Lattice Biologics (CVE:LBL) and Aequus Pharmaceuticals (CVE:AQS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and earnings.

Profitability

This table compares Lattice Biologics and Aequus Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Lattice BiologicsN/AN/AN/A
Aequus PharmaceuticalsN/AN/AN/A

Analyst Ratings

This is a summary of current ratings for Lattice Biologics and Aequus Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Lattice Biologics0000N/A
Aequus Pharmaceuticals0000N/A

Earnings and Valuation

This table compares Lattice Biologics and Aequus Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lattice BiologicsC$2.46 million2.34C$-1,795,052.00C($0.01)-3.21
Aequus PharmaceuticalsC$2.28 million11.80C$-2,462,174.00C($0.02)-10.91

Lattice Biologics has higher revenue and earnings than Aequus Pharmaceuticals. Aequus Pharmaceuticals is trading at a lower price-to-earnings ratio than Lattice Biologics, indicating that it is currently the more affordable of the two stocks.

Summary

Lattice Biologics beats Aequus Pharmaceuticals on 4 of the 5 factors compared between the two stocks.

Lattice Biologics (CVE:LBL) and (THCX.V) (CVE:THCX) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and earnings.

Profitability

This table compares Lattice Biologics and (THCX.V)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Lattice BiologicsN/AN/AN/A
(THCX.V)N/AN/AN/A

Analyst Ratings

This is a summary of current ratings for Lattice Biologics and (THCX.V), as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Lattice Biologics0000N/A
(THCX.V)0000N/A

Earnings and Valuation

This table compares Lattice Biologics and (THCX.V)'s gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lattice BiologicsC$2.46 million2.34C$-1,795,052.00C($0.01)-3.21
(THCX.V)N/AN/AN/AN/AN/A

(THCX.V) has lower revenue, but higher earnings than Lattice Biologics.

Summary

Lattice Biologics beats (THCX.V) on 1 of the 1 factors compared between the two stocks.

Lattice Biologics (CVE:LBL) and 31444 (CNSX:GLH) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and earnings.

Profitability

This table compares Lattice Biologics and 31444's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Lattice BiologicsN/AN/AN/A
31444N/AN/AN/A

Analyst Ratings

This is a summary of current ratings for Lattice Biologics and 31444, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Lattice Biologics0000N/A
314440000N/A

Earnings and Valuation

This table compares Lattice Biologics and 31444's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lattice BiologicsC$2.46 million2.34$-1,795,052.00C($0.01)-3.21
31444N/AN/AN/AN/AN/A

31444 has lower revenue, but higher earnings than Lattice Biologics.

Summary

Lattice Biologics beats 31444 on 1 of the 1 factors compared between the two stocks.

Lattice Biologics (CVE:LBL) and 438280 (CNSX:ACG) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and earnings.

Analyst Ratings

This is a summary of current ratings for Lattice Biologics and 438280, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Lattice Biologics0000N/A
4382800000N/A

Profitability

This table compares Lattice Biologics and 438280's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Lattice BiologicsN/AN/AN/A
438280N/AN/AN/A

Earnings and Valuation

This table compares Lattice Biologics and 438280's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lattice BiologicsC$2.46 million2.34C$-1,795,052.00C($0.01)-3.21
438280N/AN/AN/AN/AN/A

438280 has lower revenue, but higher earnings than Lattice Biologics.

Summary

Lattice Biologics beats 438280 on 1 of the 1 factors compared between the two stocks.


Lattice Biologics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
SUGR
SugarBud Craft Growers Corp. (SUGR.V)
0.7$0.08-6.3%C$11.81 millionC$66,906.00-0.08Gap Up
NU
NeutriSci International
0.5$0.15-0.0%C$8.65 millionC$69,626.00-11.15Upcoming Earnings
Gap Down
AQS
Aequus Pharmaceuticals
0.9$0.24-4.2%C$6.03 millionC$2.28 million-10.91
THCX
(THCX.V)
0.6$5.30-6.2%C$0.00N/A0.00High Trading Volume
GLH
31444
0.4N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
ACG
438280
0.6N/AN/AC$0.00N/A0.00Gap Down
HC
815446
0.5N/AN/A$0.00N/A0.00Gap Down
BIO
Bio-Rad Laboratories
0.5N/AN/A$0.00N/A0.00High Trading Volume
BBM
Blueberries Medical
0.6N/AN/A$0.00N/A0.00High Trading Volume
LOVE
Cannara Biotech
0.7N/AN/A$0.00N/A0.00High Trading Volume
CALI
China Auto Logistics
1.3N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
MJ
ETFMG Alternative Harvest ETF
0.5N/AN/A$0.00N/A0.00Gap Down
BOSS
Global X Founder-Run Companies ETF
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
LHS
Liberty Health Sciences
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
LIB
Liberty Leaf
0.5N/AN/AC$0.00N/A0.00High Trading Volume
News Coverage
Gap Down
MMEN
Medmen Enterprises
0.6N/AN/A$0.00N/A0.00High Trading Volume
RQB
Ravenquest Biomed
0.6N/AN/A$0.00N/A0.00High Trading Volume
TGIF
SoFi Weekly Income ETF
0.6N/AN/A$0.00N/A0.00High Trading Volume
Valeant Pharmaceuticals International logo
VRX
Valeant Pharmaceuticals International
0.5N/AN/AC$0.00N/A0.00
VRT
Vertiv
0.5N/AN/A$0.00N/A0.00Gap Down
This page was last updated on 3/4/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.